` IOBT (IO Biotech Inc) vs S&P 500 Comparison - Alpha Spread

IOBT
vs
S&P 500

Over the past 12 months, IOBT has underperformed S&P 500, delivering a return of -25% compared to the S&P 500's +14% growth.

Stocks Performance
IOBT vs S&P 500

Loading
IOBT
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
IOBT vs S&P 500

Performance Gap Between IOBT and GSPC
HIDDEN
Show

Performance By Year
IOBT vs S&P 500

Loading
IOBT
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
IO Biotech Inc vs Peers

S&P 500
IOBT
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

IO Biotech Inc
Glance View

Market Cap
46.3m USD
Industry
Biotechnology

IO Biotech, Inc. is a clinical stage biotechnology company. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The firm develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The firm is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

IOBT Intrinsic Value
Not Available
Back to Top